1. Home
  2. CTNM

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Founded: 2009 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 394.8M IPO Year: 2024
Target Price: $28.00 AVG Volume (30 days): 119.1K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.02 EPS Growth: N/A
52 Week Low/High: $13.27 - $16.46 Next Earning Date: 05-16-2024
Revenue: $50,000,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: